The New Agents Committee (NAC) was set up by the Drug Development Office (DDO) in 1998 to provide a one-step process for selecting new anti-cancer treatments and diagnostics and taking them into early clinical trials.

The NAC will consider proposals from individuals based in academic institutions and industry collaborators for:

• the late stage preclinical development of a novel agent for clinical trial; and/or
• the testing of a novel agent in mechanistic/Phase I clinical trial; and/or
the testing of a novel agent in early Phase II clinical trial.

All submissions to and meetings of the NAC are confidential.

For further details on how to apply for funding from the NAC, click here.